International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention

Cancer Letters

Volumn 278, Issue 1, 2009, Pages 1-2

  Arbyn, Marc ^a,b   Cuzick, Jack ^c  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cervical cancer; Cochrane reviews; Human papilloma virus; Primary screening; Randomised trials

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; PROTEIN P16;

CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONSENSUS; CYTODIAGNOSIS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 63449111864     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.002     Document Type: Review

References (9)

1. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., Ratnam S., Coutlee F., and Franco E.L. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357 (2007) 1579-1588
2. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., Radberg T., Strander B., Forslund O., Hansson B.G., Rylander E., and Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357 (2007) 1589-1597
3. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 S3 (2006) 78-89
4. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., Szarewski A., Birembaut P., Kulasingam S., Sasieni P., and Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119 (2006) 1095-1101
5. Schatzkin A., Connor R.J., Taylor P.R., and Bunnag B. Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. Am. J. Epidemiol. 125 (1987) 672-678
6. Bulkmans N., Berkhof J., Rozendaal L., van Kemenade F., Boeke A., Bulk S., Voorhorst F., Verheijen R., van Groningen K., Boon M., Ruitinga W., van Ballegooijen M., Snijders P., and Meijer C. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007) 796-802
7. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., Mielzynska-Lohnas I., Rush B.B., and Schiffman M.A. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer Inst. 95 (2003) 46-52
8. Cuzick J., Szarewski A., Mesher D., Cadman L., Austin J., Perryman K., Ho L., Terry G., Sasieni P., and Soutter W.P. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - results from the Hammersmith study. Int. J. Cancer 122 (2008) 2294-2300
9. M. Arbyn, J. Dillner, U. Schenck, P. Nieminen, E. Weiderpass, D. Da Silva, J. Jordan, G. Ronco, E. McGoogan, J. Patnick, P. Sparen, A. Herbert, C. Bergeron, Chapter 3: methods for screening and diagnosis, in: M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, N. Segnan, H. Wiener, J. Daniel, L. von Karsa,(Eds.), European Guidelines for Quality Assurance in Cervical Cancer Screening and European Commission, Office for official Publications of the European Communities, Luxembourg, 2008, pp. 69-152.